Anti-CD20 antibody treatment of non-Hodgkin lymphomas

被引：22

作者：

Engelhard, Marianne ^{[1
]}

机构：

[1] Univ Hosp, Dept Radiotherapy, D-45122 Essen, Germany

来源：

CLINICAL IMMUNOLOGY | 2016年 / 172卷

关键词：

Non-Hodgkin lymphoma; Immunotherapy; CD20; antigen; Anti-CD20; antibody; Rituximab; CHRONIC LYMPHOCYTIC-LEUKEMIA; B-CELL LYMPHOMA; RANDOMIZED CONTROLLED-TRIAL; ADVANCED FOLLICULAR LYMPHOMA; CHEMOTHERAPY PLUS RITUXIMAB; CHOP-LIKE CHEMOTHERAPY; REFRACTORY LOW-GRADE; MONOCLONAL-ANTIBODY; OPEN-LABEL; EARLY-STAGE;

D O I：

10.1016/j.clim.2016.08.011

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The CD20 antigen characteristic for mature B-cell is also expressed on B-cell Non-Hodgkin lymphomas (NHL). It thus presents a possible target for immunotherapy. NHL respond readily to radio- and/or chemotherapy but this standard treatment bears a high risk of relapse. The specific monoclonal anti-CD20-antibody Rituximab, the first to be approved for clinical use, could be shown to improve response rates, response duration, and survival in NHL when combined with standard therapy. This review details the development, clinical application, and future perspectives of anti-CD20-antibody treatment of NHL, thereby proving the efficiency of immunotherapy via targeting of a tumor associated antigen. (C) 2016 Elsevier Inc. All rights reserved.

引用

页码：101 / 104

页数：4

共 53 条

[1] Rituximab versus a watch-and-wait approach in patients with advanced- stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial [J].

Ardeshna, Kirit M. ;

Qian, Wendi ;

Smith, Paul ;

Braganca, Nivette ;

Lowry, Lisa ;

Patrick, Pip ;

Warden, June ;

Stevens, Lindsey ;

Pocock, Christopher F. E. ;

Miall, Fiona ;

Cunningham, David ;

Davies, John ;

Jack, Andrew ;

Stephens, Richard ;

Walewski, Jan ;

Ferhanoglu, Burhan ;

Bradstock, Ken ;

Linch, David C. .

LANCET ONCOLOGY, 2014, 15 (04) :424-435

[2]

Bello Celeste, 2007, Hematology Am Soc Hematol Educ Program, P233

[3] Direct Effect of Rituximab in B-Cell-Derived Lymphoid Neoplasias: Mechanism, Regulation, and Perspectives [J].

Bezombes, Christine ;

Fournie, Jean-Jacques ;

Laurent, Guy .

MOLECULAR CANCER RESEARCH, 2011, 9 (11) :1435-1442

[4] Transformed follicular non-Hodgkin lymphoma [J].

Casulo, Carla ;

Burack, W. Richard ;

Friedberg, Jonathan W. .

BLOOD, 2015, 125 (01) :40-47

[5] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[6] Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte [J].

Coiffier, Bertrand ;

Thieblemont, Catherine ;

Van Den Neste, Eric ;

Lepeu, Gerard ;

Plantier, Isabelle ;

Castaigne, Sylvie ;

Lefort, Sophie ;

Marit, Gerald ;

Macro, Margaret ;

Sebban, Catherine ;

Belhadj, Karim ;

Bordessoule, Dominique ;

Ferme, Christophe ;

Tilly, Herve .

BLOOD, 2010, 116 (12) :2040-2045

[7] Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG) [J].

Cramer, Paula ;

Langerbeins, Petra ;

Eichhorst, Barbara ;

Hallek, Michael .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 96 (01) :9-18

[8]

DILLMAN RO, 1982, BLOOD, V59, P1036

[9] Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis [J].

Fleury, I. ;

Chevret, S. ;

Pfreundschuh, M. ;

Salles, G. ;

Coiffier, B. ;

van Oers, M. H. J. ;

Gisselbrecht, C. ;

Zucca, E. ;

Herold, M. ;

Ghielmini, M. ;

Thieblemont, C. .

ANNALS OF ONCOLOGY, 2016, 27 (03) :390-397

[10] Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial [J].

Fowler, Nathan H. ;

Davis, R. Eric ;

Rawal, Seema ;

Nastoupil, Loretta ;

Hagemeister, Fredrick B. ;

McLaughlin, Peter ;

Kwak, Larry W. ;

Romaguera, Jorge E. ;

Fanale, Michelle A. ;

Fayad, Luis E. ;

Westin, Jason R. ;

Shah, Jatin ;

Orlowski, Robert Z. ;

Wang, Michael ;

Turturro, Francesco ;

Oki, Yasuhiro ;

Claret, Linda C. ;

Feng, Lei ;

Baladandayuthapani, Veerabhadran ;

Muzzafar, Tariq ;

Tsai, Kenneth Y. ;

Samaniego, Felipe ;

Neelapu, Sattva S. .

LANCET ONCOLOGY, 2014, 15 (12) :1311-1318

← 1 2 3 4 5 6 →